Department of Pharmacology, School of Medicine, University of California at San Diego, La Jolla, California 92093, USA.
J Biol Chem. 2011 Apr 29;286(17):14830-41. doi: 10.1074/jbc.M110.214270. Epub 2011 Mar 1.
Caveolin (Cav) proteins in the plasma membrane have numerous binding partners, but the determinants of these interactions are poorly understood. We show here that Cav-3 has a small ubiquitin-like modifier (SUMO) consensus motif (ΨKX(D/E, where Ψ is a hydrophobic residue)) near the scaffolding domain and that Cav-3 is SUMOylated in a manner that is enhanced by the SUMO E3 ligase PIASy (protein inhibitor of activated STAT-y). Site-directed mutagenesis revealed that the consensus site lysine is the preferred SUMOylation site but that mutation of all lysines is required to abolish SUMOylation. Co-expression of a SUMOylation-deficient mutant of Cav-3 with β-adrenergic receptors (βARs) alters the expression level of β(2)ARs but not β(1)ARs following agonist stimulation, thus implicating Cav-3 SUMOylation in the mechanisms for β(2)AR but not β(1)AR desensitization. Expression of endothelial nitric-oxide synthase (NOS3) was not altered by the SUMOylation-deficient mutant. Thus, SUMOylation is a covalent modification of caveolins that influence the regulation of certain signaling partners.
质膜中的窖蛋白(Cav)具有许多结合伴侣,但这些相互作用的决定因素尚不清楚。我们在此表明,Cav-3 在支架结构域附近具有一个小的泛素样修饰(SUMO)共有基序(ΨKX(D / E,其中 Ψ 是疏水性残基)),并且 Cav-3 的 SUMO 化方式被 SUMO E3 连接酶 PIASy(激活 STAT-y 的蛋白抑制剂)增强。定点诱变表明,共有基序赖氨酸是首选的 SUMO 化位点,但要消除 SUMO 化则需要突变所有赖氨酸。与β-肾上腺素能受体(βAR)共表达 Cav-3 的 SUMO 化缺陷突变体后,激动剂刺激后β(2)AR 的表达水平发生改变,但β(1)AR 则没有,这表明 Cav-3 SUMO 化参与了β(2)AR 而不是β(1)AR 脱敏的机制。内皮型一氧化氮合酶(NOS3)的表达不受 SUMO 化缺陷突变体的影响。因此,SUMO 化是窖蛋白的一种共价修饰,影响某些信号伴侣的调节。